EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PTEN deficiency confers sensitivity to ATR inhibitor–based treatment in high-grade serous ovarian cancer

Jie Hao, Bose Kochupurakkal, Timothy B Branigan, Ozge Sezin Somuncu, Renyan Liu, Heta Jadhav, Alexandre André B A da Costa, Yuqing Jiao, Jenny Z Yu, David B Martignetti, Golbahar Sadatrezaei, Sirisha Mukkavalli und 16 weitere

Journal of Clinical Investigation · 17.08.2026 · 136 (16)

DOI: 10.1172/jci197645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.07.2026. Verfasst von Jie Hao und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, PTEN Phosphohydrolase, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ataxia telangiectasia and Rad3-related (ATR) inhibition is under evaluation for the treatment of high-grade serous ovarian cancer (HGSOC) to reverse acquired resistance to poly (ADP-ribose) polymerase (PARP) inhibition and to exacerbate chemotherapy-induced replicative stress. Here, we define PTEN deficiency as a predictive biomarker for the response to ATR inhibition, as monotherapy and in combination with PARP inhibition or gemcitabine. In response to ATR inhibition and compared with PTEN-proficient cells, PTEN-deficient cells are prone to (a) uncoupling of DNA polymerase and helicase activities, leading to excessive ssDNA and replication stress; (b) cytoplasmic sequestration of checkpoint kinase 1 (CHK1), compromising cell-cycle checkpoint control with reduced compensatory effects by ataxia-telangiectasia mutated (ATM) and DNA–dependent proteinase K (DNA-PK), leading to mitotic catastrophe; and (c) reduced DNA repair protein RAD51 homolog 1 (RAD51) recruitment, exacerbating replication fork instability, also leading to lethality. Retrospective analyses revealed that patients with HGSOC who expressed low PTEN levels experienced greater clinical benefit on ATR inhibitor–based trials than did those with high PTEN levels. These results justify prospective trials evaluating ATR inhibition as a therapeutic strategy for PTEN-deficient tumors. Hao et al. have demonstrated that PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in preclinical models and clinical trials of high-grade serous ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsPTEN PhosphohydrolaseOvarian NeoplasmsCystadenocarcinoma, SerousNeoplasm ProteinsFemaleHumansCheckpoint Kinase 1AnimalsPoly(ADP-ribose) Polymerase InhibitorsCell Line, TumorRad51 RecombinaseMiceDeoxycytidine

Stichwörter der Autor:innen

CancerCell biologyClinical ResearchDNA repairDrug therapyOncology

Substanzen

Ataxia Telangiectasia Mutated ProteinsPTEN PhosphohydrolaseATR protein, humanPTEN protein, humanCheckpoint Kinase 1CHEK1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsRad51 RecombinaseRAD51 protein, humanDeoxycytidine

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Center for DNA Damage and Repair, DFCI, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, DFCI and Harvard Medical School, Boston, Massachusetts, USA.
  • Belfer Center for Applied Cancer Science, DFCI, Boston, Massachusetts, USA.
  • Department of Data Science, DFCI and Harvard H.T. Chan School of Public Health, Boston, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Merck KGaA
  • Ludwig Center at Harvard

Zitieren

APA

Hao, J., Kochupurakkal, B., Branigan, T. B., Somuncu, O. S., Liu, R., Jadhav, H., da Costa, A. A. B. A., Jiao, Y., Yu, J. Z., Martignetti, D. B., Sadatrezaei, G., Mukkavalli, S., Gokhale, P. C., Cheng, S. C., Skates, S. J., Nasioudis, D., Konstantinopoulos, P. A., Liu, J. F., Gaillard, S., …, & Shapiro, G. I. (2026). PTEN deficiency confers sensitivity to ATR inhibitor–based treatment in high-grade serous ovarian cancer. Journal of Clinical Investigation, 136(16). https://doi.org/10.1172/jci197645

Vancouver

Hao J, Kochupurakkal B, Branigan TB, Somuncu OS, Liu R, Jadhav H, et al. PTEN deficiency confers sensitivity to ATR inhibitor–based treatment in high-grade serous ovarian cancer. Journal of Clinical Investigation. 2026;136(16). doi:10.1172/jci197645

BibTeX
@article{Hao2026,
  author = {Hao, Jie and Kochupurakkal, Bose and Branigan, Timothy B and Somuncu, Ozge Sezin and Liu, Renyan and Jadhav, Heta and da Costa, Alexandre André B A and Jiao, Yuqing and Yu, Jenny Z and Martignetti, David B and Sadatrezaei, Golbahar and Mukkavalli, Sirisha and Gokhale, Prafulla C and Cheng, Su-Chun and Skates, Steven J and Nasioudis, Dimitrios and Konstantinopoulos, Panagiotis A and Liu, Joyce F and Gaillard, Stephanie and Giuntoli, Robert L and Martin, Lainie and Tanyi, Janos and Latif, Nawar and Heller, Ian and Simpkins, Fiona and Parmar, Kalindi and D'Andrea, Alan D and Shapiro, Geoffrey I},
  title = {PTEN deficiency confers sensitivity to ATR inhibitor–based treatment in high-grade serous ovarian cancer},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {16},
  doi = {10.1172/jci197645}
}
Kostenlos starten →